Join to View Full Profile
55 Fruit StBoston, MA 02114
Phone+1 617-724-4000
Dr. Barnes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2026
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Ant...Hazim S Ababneh, Andrea K Ng, Joshua Wan, Tyler Walburn, Lin Zhu
International Journal of Radiation Oncology, Biology, Physics. 2025-04-03 - Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
Blood. 2025-04-03 - A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.Mwanasha H Merrill, Robert A Redd, David C Fisher, Jeremy S Abramson, Jeffrey Barnes
Leukemia & Lymphoma. 2025-03-25
Abstracts/Posters
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
